NSEDisclosure under SEBI Takeover Regulations30 Jun 2026 · 30 Jun 2026, 03:21 pm
Disclosure under SEBI Takeover Regulations
Jagsonpal Pharmaceuticals Limited · JAGSNPHARM
✦ AI SummaryRegulatory
Jagsonpal Pharmaceuticals Limited has submitted a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, stating that the promoters have not created any encumbrance over the shares of the company as on March 31, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jagsonpal Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Attachments (1)
📄pdf
Download →
team_sandeshc_23062026131250_37.pdf
View document text
April 09, 2026
The Department of Corporate Services- Listing The Department of Corporate Services- Listing
BSE Ltd, National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G,
Dalal Street, Bandra Kurla Complex, Bandra (E)
Mumbai-400 001 Mumbai – 400 051
Scrip Code: 507789 Symbol: JAGSNPHARM
Dear Sir/ Madam,
Subject: Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011
In terms of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 we are hereby enclosing
the Annual disclosures of our promoters under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and
Takeovers) Regulations, 2011 for the year ended on March 31, 2026 for compliance.
We request you to take the above on record.
Thanking you,
For Jagsonpal Pharmaceuticals Limited
Pratham Rawal
Company Secretary & Compliance officer
Docusign Envelope ID: 4C59C8B5-DB81-462E-B672-CB1E285CDBB7
Infinity Holdings
Apex Fund and Corporate Services (Mauritius) Ltd
6th floor, Two Tribeca, Tribeca Central, Trianon, 72261, Mauritius
April 06, 2026
The Manager The Manager
BSE Ltd, National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G,
Dalal Street Bandra Kurla Complex,
Mumbai-400 001 Bandra (E) Mumbai – 400 051
Scrip Code: 507789 Symbol: JAGSNPHARM
Sub: Disclosure by Promoters of Listed Company under Regulation 31 (4) of SEBI (Substantial Acquisition
of Shares and Takeovers) Regulations, 2011
Dear Sir/Madam,
Pursuant to the provisions of Regulation 31 (4) of the SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011, We, Infinity Holdings along with persons acting with concert of Jagsonpal Pharmaceuticals
Limited, hereby declare that we have not made any encumbrance of shares, directly or indirectly during the
financial year ended March 31, 2026.
Kindly take the above-mentioned information on your record.
For Infinity Holdings
Ahmad Tariq Hossanee
Director
Encl: as above
Infinity Capital (Formerly known as Infinity Holdings Sidecar I)
Infinity Portfolio Holdings
The Audit Committee
Jagsonpal Pharmaceuticals Limited
Innov8 3rd Floor, Plot No. 211, Okhla Phase-3,
New Delhi, Delhi, 110020
The Company Secretary,
Jagsonpal Pharmaceuticals Limited
Innov8 3rd Floor, Plot No. 211, Okhla Phase-3,
New Delhi, Delhi, 110020
April 09, 2026
The Manager The Manager
BSE Limited, National Stock Exchange of India Ltd.,
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor,
Dalal Street, Bandra-Kurla Complex,
Mumbai 400 001. Bandra (E), Mumbai 400 051.
Scrip code: 507789 Scrip code: JAGSNPHARM
Sub: Declaration under Regulation 31(4) of the SEBI (Substantial Acquisition of
Shares and Takeovers) Regulations, 2011
Dear Sir / Madam
In terms of Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011, we, Rajpal Singh Kochhar and Aresko Progressive Private Limited, the
Promoters of the Jagsonpal Pharmaceuticals Limited (“Company”), based on the information
received from other members of the promoter group of the Company (as listed in Annexure A
hereto) hereby declare that the members of the promoter and promoter group of the Company
have not created any encumbrance over the shares of the Company, directly or indirectly, as
on March 31, 2026
Kindly take the same on record.
Thanking You
Rajpal Singh Kochhar
For and on behalf of Aresko Progressive Private Limited
The Audit Committee
Jagsonpal Pharmaceuticals Limited
Innov8 3rd Floor, Plot No. 211, Okhla Phase-3,
New Delhi, Delhi, 110020
Company Secretary
Jagsonpal Pharmaceuticals Limited
Innov8 3rd Floor, Plot No. 211, Okhla Phase-3,
New Delhi, Delhi, 110020
Annexure A
S. Name person acting in concert Category No of shares
1. Rajpal Singh Kochhar Promoter 30,30,400
2. Aresko Progressive Private Limited Promoter 1,33,35,635
(Trustee of Aresko Progressive Trust, a in
the capacity of representative partner of
J&P Investments Partnership)
3. Prithipal Singh Kochhar Promoter Group 2,69,675
4. Inderpal Singh Kochhar Promoter Group 1,83,750
5. Ishpinder Kaur Kochhar Promoter Group
6. Rakshit Organisational Operations and Promoter Group
Transformations Private Limited
7. Aresko Life Sciences Private Limited Promoter Group
8. Aresko Restaurants Private Limited Promoter Group
9. Aresko Services Limited Promoter Group
10. Aresko Family Private Limited Promoter Group
11. Aresko Realtors Private Limited Promoter Group
12. Sewara Buildtech Private Limited Promoter Group
13. Naari Pharma Private Limited Promoter Group
14. I. K. Enterprises Private Limited Promoter Group
15. Alga Hospitality Private Limited Promoter Group
16. Aresko Estates Private Limited Promoter Group
17. Bagri Fort Resorts Private Limited Promoter Group
18. Mahar Palace Hotel & Spa Private Limited Promoter Group
19. Kila Tatarpur Hotels Private Limited Promoter Group
20. Suvinys Developers Private Ltd Promoter Group
21. Jaswant Singh Kochhar Foundation Promoter Group
22. RPSK Partners LLP Promoter Group
23. Sewara Partners LLP Promoter Group
24. Aresko Associates LLP Promoter Group
25. Aresko Pharma LLP Promoter Group
26. Aresko Global LLP Promoter Group
27. Sewara Realtech LLP Promoter Group
28. RPSK Strategic LLP Promoter Group
29. Y Johnson LLP Promoter Group
30. Aresko Management LLP Promoter Group
31. Aresko Properties LLP Promoter Group
32. Sewara Management LLP Promoter Group
33. RPSK Realtech LLP Promoter Group
34. Aresko Progressive Trust (Represented by Promoter Group
Trustee, Aresko Progressive Pvt. Ltd)
35. Aresko Family Trust Promoter Group
36. Aresko Realtors Trust Promoter Group
37. Sewara Buildtech Trust Promoter Group
38. Aresko Progressive Pvt. Ltd Promoter Group